Huadong Medicine reports strong Q3 growth, innovative products boost revenue

Huadong Medicine Co., Ltd. reported total operating revenue of 32.664 bn yuan for the first nine months of 2025, a 3.77% year-on-year increase. Net profit attributable to shareholders rose by 7.24% to 2.748 bn yuan during the same period. For Q3 2025 alone, operating revenue reached 10.989 bn yuan, up 4.53% year-on-year, with net profit attributable to shareholders increasing by 7.71% to 933 m yuan.

The company's core pharmaceutical subsidiary, Zhongmei Huadong, saw its operating revenue grow by 11.10% to 11.045 bn yuan, with net profit to the parent company up 15.62% to 2.475 bn yuan for the first nine months of 2025. Innovative products contributed significantly, with sales and agency services totaling 1.675 bn yuan, a 62% year-on-year increase. Key R&D milestones included five marketing approvals and eighteen IND approvals in China or the U.S. since 2025.

Despite overall growth, the medical aesthetics segment experienced a 17.90% decline in revenue to 1.568 bn yuan for January-September 2025, reflecting global economic adjustments and intensified competition. Conversely, the industrial microbiology segment demonstrated robust growth, with a 28.48% year-on-year increase in revenue, boosted by expansion into overseas markets.